human tumor brain cell line u87 Search Results


99
ATCC human glioblastoma cells u87 mg u87
Human Glioblastoma Cells U87 Mg U87, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human glioblastoma cells u87 mg u87/product/ATCC
Average 99 stars, based on 1 article reviews
human glioblastoma cells u87 mg u87 - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier

95
Fujirebio Inc células u87 y sk n mc se realizó un elisa para la proteína viral p24
Células U87 Y Sk N Mc Se Realizó Un Elisa Para La Proteína Viral P24, supplied by Fujirebio Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/células u87 y sk n mc se realizó un elisa para la proteína viral p24/product/Fujirebio Inc
Average 95 stars, based on 1 article reviews
células u87 y sk n mc se realizó un elisa para la proteína viral p24 - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier

99
ATCC mcf7 u 87
Mcf7 U 87, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mcf7 u 87/product/ATCC
Average 99 stars, based on 1 article reviews
mcf7 u 87 - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier

99
ATCC transfection human glioblastoma cell lines
Transfection Human Glioblastoma Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/transfection human glioblastoma cell lines/product/ATCC
Average 99 stars, based on 1 article reviews
transfection human glioblastoma cell lines - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier

99
ATCC glioma cell lines
Glioma Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/glioma cell lines/product/ATCC
Average 99 stars, based on 1 article reviews
glioma cell lines - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier

99
ATCC human cell lines
Human Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human cell lines/product/ATCC
Average 99 stars, based on 1 article reviews
human cell lines - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier

90
Virco Pharmaceuticals u87.cd4.r5/r4
U87.Cd4.R5/R4, supplied by Virco Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/u87.cd4.r5/r4/product/Virco Pharmaceuticals
Average 90 stars, based on 1 article reviews
u87.cd4.r5/r4 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

99
ATCC human cancer cell lines
Human Cancer Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human cancer cell lines/product/ATCC
Average 99 stars, based on 1 article reviews
human cancer cell lines - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier

90
Procell Inc human gbm cell line u87
Human Gbm Cell Line U87, supplied by Procell Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human gbm cell line u87/product/Procell Inc
Average 90 stars, based on 1 article reviews
human gbm cell line u87 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Genechem u87 cells
TIM-3 is one of the most highly elevated immune checkpoints in GBM and is expressed by both non-tumor and tumor cells (A) The expression analyses of immune checkpoints in GBM, in comparison with non-tumor tissue and LGG, identified 7 overlapping elevated immune checkpoints, including 2 co-inhibitory immune checkpoints ( TIM- 3 and LAIR1 ) and 5 co-stimulatory immune checkpoints ( SLAMF8 , CD300A , TYPOBP , CD58 , and BTN3A2 ) (TCGA-seq, GBM, n = 155; LGG, n = 515; non-tumor, n = 4; GSE16011 , GBM, n = 155; LGG, n = 116; non-tumor, n = 8). (B) RT-qPCR analyses of CTLA4 , TIM3 , LAIR1 , PD1 , PDL1 , PDL2 and ID O 1 in clinical GBM samples (n = 10, means ± SEM, one-way ANOVA). (C) Immunohistochemical staining (Left, scale bar, 50 μm) and analyses (Right, non-tumor, n = 13; Grade II, n = 6; Grade III, n = 17; Grade IV, n = 77; means ± SEM, one-way ANOVA) of TIM-3 in clinical samples. (D) The Kaplan-Meier analyses of clinical glioma samples reveal the correlation of TIM-3 with poor prognosis in GBM (TIM-3 high vs. low, p = 0.0003; log rank test). (E) CIBERSORT analysis of non-tumor cell populations associated with high TIM-3 expression in TCGA RNA-seq GBM dataset (Pearson correlation analysis). (F) The tSNE plot of TIM-3 expression profile in GBM and immune cells with single-cell RNA-seq data ( GSE131928 ). (G) Representative immunofluorescence images of TIM-3 and GFAP staining in clinical GBM samples (scale bar, 50 μm). (H) FACS analysis shows that clinical GBM samples contained low CD45, and high TIM-3 cell populations (n = 7). (I) qPCR analysis of TIM-3 mRNA expression in NHA, indicated glioma cell lines <t>(U87,</t> U251, and LN229), primary glioma cells (PGC1228, PGC21, PGC24, and PGC40), and PBMC from patients with glioma (G-PBMC1 and G-PBMC2) and healthy donor (PBMC1 and PBMC2) (n = 3, means ± SEM, one-way ANOVA). (J) Western blot analyses of TIM-3 in NHA, indicated glioma cell lines, and primary glioma adherent and neurosphere cells (n = 3, means ± SEM, one-way ANOVA). (K) The schematic diagram describing the co-culture system of THP-1-derived anti-inflammatory/pro-tumorigenic (M2) macrophages and glioma cells (left panel), and representative western blot images of TIM-3 in indicated glioma cells cocultured with THP-1-derived anti-inflammatory/pro-tumorigenic TAMs (right panel). (ns p ≥ 0.05, ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗∗ p < 0.0001).
U87 Cells, supplied by Genechem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/u87 cells/product/Genechem
Average 90 stars, based on 1 article reviews
u87 cells - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

86
LGC Standards u87 human glioma cells
TIM-3 is one of the most highly elevated immune checkpoints in GBM and is expressed by both non-tumor and tumor cells (A) The expression analyses of immune checkpoints in GBM, in comparison with non-tumor tissue and LGG, identified 7 overlapping elevated immune checkpoints, including 2 co-inhibitory immune checkpoints ( TIM- 3 and LAIR1 ) and 5 co-stimulatory immune checkpoints ( SLAMF8 , CD300A , TYPOBP , CD58 , and BTN3A2 ) (TCGA-seq, GBM, n = 155; LGG, n = 515; non-tumor, n = 4; GSE16011 , GBM, n = 155; LGG, n = 116; non-tumor, n = 8). (B) RT-qPCR analyses of CTLA4 , TIM3 , LAIR1 , PD1 , PDL1 , PDL2 and ID O 1 in clinical GBM samples (n = 10, means ± SEM, one-way ANOVA). (C) Immunohistochemical staining (Left, scale bar, 50 μm) and analyses (Right, non-tumor, n = 13; Grade II, n = 6; Grade III, n = 17; Grade IV, n = 77; means ± SEM, one-way ANOVA) of TIM-3 in clinical samples. (D) The Kaplan-Meier analyses of clinical glioma samples reveal the correlation of TIM-3 with poor prognosis in GBM (TIM-3 high vs. low, p = 0.0003; log rank test). (E) CIBERSORT analysis of non-tumor cell populations associated with high TIM-3 expression in TCGA RNA-seq GBM dataset (Pearson correlation analysis). (F) The tSNE plot of TIM-3 expression profile in GBM and immune cells with single-cell RNA-seq data ( GSE131928 ). (G) Representative immunofluorescence images of TIM-3 and GFAP staining in clinical GBM samples (scale bar, 50 μm). (H) FACS analysis shows that clinical GBM samples contained low CD45, and high TIM-3 cell populations (n = 7). (I) qPCR analysis of TIM-3 mRNA expression in NHA, indicated glioma cell lines <t>(U87,</t> U251, and LN229), primary glioma cells (PGC1228, PGC21, PGC24, and PGC40), and PBMC from patients with glioma (G-PBMC1 and G-PBMC2) and healthy donor (PBMC1 and PBMC2) (n = 3, means ± SEM, one-way ANOVA). (J) Western blot analyses of TIM-3 in NHA, indicated glioma cell lines, and primary glioma adherent and neurosphere cells (n = 3, means ± SEM, one-way ANOVA). (K) The schematic diagram describing the co-culture system of THP-1-derived anti-inflammatory/pro-tumorigenic (M2) macrophages and glioma cells (left panel), and representative western blot images of TIM-3 in indicated glioma cells cocultured with THP-1-derived anti-inflammatory/pro-tumorigenic TAMs (right panel). (ns p ≥ 0.05, ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗∗ p < 0.0001).
U87 Human Glioma Cells, supplied by LGC Standards, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/u87 human glioma cells/product/LGC Standards
Average 86 stars, based on 1 article reviews
u87 human glioma cells - by Bioz Stars, 2026-03
86/100 stars
  Buy from Supplier

94
CLS Cell Lines Service GmbH u87 mg u87 cell lines
Effect of arginine deprivation on glioblastoma cells. a Cell growth of U251 ( upper panel ) and <t>U87</t> ( lower panel ) cells cultivated in control, -Arg, -Lys and conditions. b U251 cell viability assessed under deprivation and re-supplementation conditions, as indicated. Upper and lower panels , arginine and lysine re-supplementation, respectively. 100 %, the number of the viable cells at time 0. Data in a and b are means ± SD; *** and *Statistical relevance p < 0.001 and p < 0.05, respectively
U87 Mg U87 Cell Lines, supplied by CLS Cell Lines Service GmbH, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/u87 mg u87 cell lines/product/CLS Cell Lines Service GmbH
Average 94 stars, based on 1 article reviews
u87 mg u87 cell lines - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

Image Search Results


TIM-3 is one of the most highly elevated immune checkpoints in GBM and is expressed by both non-tumor and tumor cells (A) The expression analyses of immune checkpoints in GBM, in comparison with non-tumor tissue and LGG, identified 7 overlapping elevated immune checkpoints, including 2 co-inhibitory immune checkpoints ( TIM- 3 and LAIR1 ) and 5 co-stimulatory immune checkpoints ( SLAMF8 , CD300A , TYPOBP , CD58 , and BTN3A2 ) (TCGA-seq, GBM, n = 155; LGG, n = 515; non-tumor, n = 4; GSE16011 , GBM, n = 155; LGG, n = 116; non-tumor, n = 8). (B) RT-qPCR analyses of CTLA4 , TIM3 , LAIR1 , PD1 , PDL1 , PDL2 and ID O 1 in clinical GBM samples (n = 10, means ± SEM, one-way ANOVA). (C) Immunohistochemical staining (Left, scale bar, 50 μm) and analyses (Right, non-tumor, n = 13; Grade II, n = 6; Grade III, n = 17; Grade IV, n = 77; means ± SEM, one-way ANOVA) of TIM-3 in clinical samples. (D) The Kaplan-Meier analyses of clinical glioma samples reveal the correlation of TIM-3 with poor prognosis in GBM (TIM-3 high vs. low, p = 0.0003; log rank test). (E) CIBERSORT analysis of non-tumor cell populations associated with high TIM-3 expression in TCGA RNA-seq GBM dataset (Pearson correlation analysis). (F) The tSNE plot of TIM-3 expression profile in GBM and immune cells with single-cell RNA-seq data ( GSE131928 ). (G) Representative immunofluorescence images of TIM-3 and GFAP staining in clinical GBM samples (scale bar, 50 μm). (H) FACS analysis shows that clinical GBM samples contained low CD45, and high TIM-3 cell populations (n = 7). (I) qPCR analysis of TIM-3 mRNA expression in NHA, indicated glioma cell lines (U87, U251, and LN229), primary glioma cells (PGC1228, PGC21, PGC24, and PGC40), and PBMC from patients with glioma (G-PBMC1 and G-PBMC2) and healthy donor (PBMC1 and PBMC2) (n = 3, means ± SEM, one-way ANOVA). (J) Western blot analyses of TIM-3 in NHA, indicated glioma cell lines, and primary glioma adherent and neurosphere cells (n = 3, means ± SEM, one-way ANOVA). (K) The schematic diagram describing the co-culture system of THP-1-derived anti-inflammatory/pro-tumorigenic (M2) macrophages and glioma cells (left panel), and representative western blot images of TIM-3 in indicated glioma cells cocultured with THP-1-derived anti-inflammatory/pro-tumorigenic TAMs (right panel). (ns p ≥ 0.05, ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗∗ p < 0.0001).

Journal: iScience

Article Title: Cancer cell intrinsic TIM-3 induces glioblastoma progression

doi: 10.1016/j.isci.2022.105329

Figure Lengend Snippet: TIM-3 is one of the most highly elevated immune checkpoints in GBM and is expressed by both non-tumor and tumor cells (A) The expression analyses of immune checkpoints in GBM, in comparison with non-tumor tissue and LGG, identified 7 overlapping elevated immune checkpoints, including 2 co-inhibitory immune checkpoints ( TIM- 3 and LAIR1 ) and 5 co-stimulatory immune checkpoints ( SLAMF8 , CD300A , TYPOBP , CD58 , and BTN3A2 ) (TCGA-seq, GBM, n = 155; LGG, n = 515; non-tumor, n = 4; GSE16011 , GBM, n = 155; LGG, n = 116; non-tumor, n = 8). (B) RT-qPCR analyses of CTLA4 , TIM3 , LAIR1 , PD1 , PDL1 , PDL2 and ID O 1 in clinical GBM samples (n = 10, means ± SEM, one-way ANOVA). (C) Immunohistochemical staining (Left, scale bar, 50 μm) and analyses (Right, non-tumor, n = 13; Grade II, n = 6; Grade III, n = 17; Grade IV, n = 77; means ± SEM, one-way ANOVA) of TIM-3 in clinical samples. (D) The Kaplan-Meier analyses of clinical glioma samples reveal the correlation of TIM-3 with poor prognosis in GBM (TIM-3 high vs. low, p = 0.0003; log rank test). (E) CIBERSORT analysis of non-tumor cell populations associated with high TIM-3 expression in TCGA RNA-seq GBM dataset (Pearson correlation analysis). (F) The tSNE plot of TIM-3 expression profile in GBM and immune cells with single-cell RNA-seq data ( GSE131928 ). (G) Representative immunofluorescence images of TIM-3 and GFAP staining in clinical GBM samples (scale bar, 50 μm). (H) FACS analysis shows that clinical GBM samples contained low CD45, and high TIM-3 cell populations (n = 7). (I) qPCR analysis of TIM-3 mRNA expression in NHA, indicated glioma cell lines (U87, U251, and LN229), primary glioma cells (PGC1228, PGC21, PGC24, and PGC40), and PBMC from patients with glioma (G-PBMC1 and G-PBMC2) and healthy donor (PBMC1 and PBMC2) (n = 3, means ± SEM, one-way ANOVA). (J) Western blot analyses of TIM-3 in NHA, indicated glioma cell lines, and primary glioma adherent and neurosphere cells (n = 3, means ± SEM, one-way ANOVA). (K) The schematic diagram describing the co-culture system of THP-1-derived anti-inflammatory/pro-tumorigenic (M2) macrophages and glioma cells (left panel), and representative western blot images of TIM-3 in indicated glioma cells cocultured with THP-1-derived anti-inflammatory/pro-tumorigenic TAMs (right panel). (ns p ≥ 0.05, ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗∗ p < 0.0001).

Article Snippet: Human: U87 cells , GeneChem , RRID: CVCL_0022.

Techniques: Expressing, Comparison, Quantitative RT-PCR, Immunohistochemical staining, Staining, RNA Sequencing, Immunofluorescence, Western Blot, Co-Culture Assay, Derivative Assay

TIM-3 increases IL6 expression via activating NF-κB signaling in glioma cells (A) Representative western blotting images of Gal-9 in conditioned medium (CM) from indicated glioma cells separately transfected with TIM-3 overexpression, control, knockdown, or siNC vector. (B) The detection (left) and quantification (right) of cytokines in culture supernatants from GSC40 transduced with TIM-3 overexpression or control vector by proteome profiler cytokine array. (C-E) Representative western blotting images of IL6 in U87 cells transduced with control (U87-NC) or TIM-3 overexpression vectors (U87-TIM3 OE), respectively, and then with indicated treatment at indicated incubation time (C, with CHX; D, with CHX after MG132 pretreatment; E, with CHX after CQ pretreatment). (F) Representative western blot images of indicated glioma cells transduced with TIM-3 overexpression vector with or without blockade of Gal-9 (10 μg/mL). (G) IL6 concentration in CM from indicated cells measured by ELISA (n = 3, means ± SEM, one-way ANOVA). (H) Representative western blot images of indicated cells incubated with indicated concentrations (ng/mL) of IL6. (I-K) The decreased growth (I, n = 3, means ± SEM, one-way ANOVA; scale bar, 50 μm), migration (J, n = 3, means ± SEM, one-way ANOVA; scale bar, 50 μm), and neurosphere formation abilities (K, upper: n = 10, extreme limiting dilution assay; lower: stem cell frequency, n = 3, means ± SEM, one-way ANOVA) of GSC40 induced by TIM-3 knockdown was partially rescued by IL6 supplement (40 ng/mL). (ns p ≥ 0.05; ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; ∗∗∗∗ p < 0.0001).

Journal: iScience

Article Title: Cancer cell intrinsic TIM-3 induces glioblastoma progression

doi: 10.1016/j.isci.2022.105329

Figure Lengend Snippet: TIM-3 increases IL6 expression via activating NF-κB signaling in glioma cells (A) Representative western blotting images of Gal-9 in conditioned medium (CM) from indicated glioma cells separately transfected with TIM-3 overexpression, control, knockdown, or siNC vector. (B) The detection (left) and quantification (right) of cytokines in culture supernatants from GSC40 transduced with TIM-3 overexpression or control vector by proteome profiler cytokine array. (C-E) Representative western blotting images of IL6 in U87 cells transduced with control (U87-NC) or TIM-3 overexpression vectors (U87-TIM3 OE), respectively, and then with indicated treatment at indicated incubation time (C, with CHX; D, with CHX after MG132 pretreatment; E, with CHX after CQ pretreatment). (F) Representative western blot images of indicated glioma cells transduced with TIM-3 overexpression vector with or without blockade of Gal-9 (10 μg/mL). (G) IL6 concentration in CM from indicated cells measured by ELISA (n = 3, means ± SEM, one-way ANOVA). (H) Representative western blot images of indicated cells incubated with indicated concentrations (ng/mL) of IL6. (I-K) The decreased growth (I, n = 3, means ± SEM, one-way ANOVA; scale bar, 50 μm), migration (J, n = 3, means ± SEM, one-way ANOVA; scale bar, 50 μm), and neurosphere formation abilities (K, upper: n = 10, extreme limiting dilution assay; lower: stem cell frequency, n = 3, means ± SEM, one-way ANOVA) of GSC40 induced by TIM-3 knockdown was partially rescued by IL6 supplement (40 ng/mL). (ns p ≥ 0.05; ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; ∗∗∗∗ p < 0.0001).

Article Snippet: Human: U87 cells , GeneChem , RRID: CVCL_0022.

Techniques: Expressing, Western Blot, Transfection, Over Expression, Control, Knockdown, Plasmid Preparation, Transduction, Incubation, Concentration Assay, Enzyme-linked Immunosorbent Assay, Migration, Limiting Dilution Assay

Journal: iScience

Article Title: Cancer cell intrinsic TIM-3 induces glioblastoma progression

doi: 10.1016/j.isci.2022.105329

Figure Lengend Snippet:

Article Snippet: Human: U87 cells , GeneChem , RRID: CVCL_0022.

Techniques: Control, Purification, Recombinant, Modification, Sterility, Cell Culture, Lysis, Transfection, Western Blot, Immunoprecipitation, Enzyme-linked Immunosorbent Assay, Proliferation Assay, Imaging, Sequencing, Real-time Polymerase Chain Reaction, Plasmid Preparation, Software, Fluorescence, Microscopy

Effect of arginine deprivation on glioblastoma cells. a Cell growth of U251 ( upper panel ) and U87 ( lower panel ) cells cultivated in control, -Arg, -Lys and conditions. b U251 cell viability assessed under deprivation and re-supplementation conditions, as indicated. Upper and lower panels , arginine and lysine re-supplementation, respectively. 100 %, the number of the viable cells at time 0. Data in a and b are means ± SD; *** and *Statistical relevance p < 0.001 and p < 0.05, respectively

Journal: Amino Acids

Article Title: Arginine deprivation affects glioblastoma cell adhesion, invasiveness and actin cytoskeleton organization by impairment of β-actin arginylation

doi: 10.1007/s00726-014-1857-1

Figure Lengend Snippet: Effect of arginine deprivation on glioblastoma cells. a Cell growth of U251 ( upper panel ) and U87 ( lower panel ) cells cultivated in control, -Arg, -Lys and conditions. b U251 cell viability assessed under deprivation and re-supplementation conditions, as indicated. Upper and lower panels , arginine and lysine re-supplementation, respectively. 100 %, the number of the viable cells at time 0. Data in a and b are means ± SD; *** and *Statistical relevance p < 0.001 and p < 0.05, respectively

Article Snippet: Human glioblastoma U251 MG (U251) and U87 MG (U87) cell lines were purchased from CLS Cell Lines Service (Germany) and monitored for correct genetic profile via microsatellite analyses according to a protocol described earlier (Peickert et al. ).

Techniques:

Arginine deprivation affects morphology of glioblastoma but not glia cells. a , b , d Rat glia, U251 and U87 cells stained with Alexa 488-phalloidin, respectively. c Micrographs of U251 cells attained with scanning electron microscope. Insets in a , b and d ~2–3× magnification of the marked areas . Bars , in a , b and d 50 μm, and in c 10 μm. e U251 cells stained with Alexa 488-phalloidin before and after re-supplementation with Arg or Lys up to 0.4 and 0.8 mM concentration, respectively. Arrows point to lamellipodia, arrowheads point to elongated cells

Journal: Amino Acids

Article Title: Arginine deprivation affects glioblastoma cell adhesion, invasiveness and actin cytoskeleton organization by impairment of β-actin arginylation

doi: 10.1007/s00726-014-1857-1

Figure Lengend Snippet: Arginine deprivation affects morphology of glioblastoma but not glia cells. a , b , d Rat glia, U251 and U87 cells stained with Alexa 488-phalloidin, respectively. c Micrographs of U251 cells attained with scanning electron microscope. Insets in a , b and d ~2–3× magnification of the marked areas . Bars , in a , b and d 50 μm, and in c 10 μm. e U251 cells stained with Alexa 488-phalloidin before and after re-supplementation with Arg or Lys up to 0.4 and 0.8 mM concentration, respectively. Arrows point to lamellipodia, arrowheads point to elongated cells

Article Snippet: Human glioblastoma U251 MG (U251) and U87 MG (U87) cell lines were purchased from CLS Cell Lines Service (Germany) and monitored for correct genetic profile via microsatellite analyses according to a protocol described earlier (Peickert et al. ).

Techniques: Staining, Microscopy, Concentration Assay

Arginine deprivation impairs cell motility. a , b Migration tracks of U251 and U87 cells, respectively. Upper panels in a and b tracks of 10 randomly chosen cells; center panels images of migrating cells, and lower panels values of migration rate and mean distance based on tracks shown in upper panels . Values are means ± SD. ***Statistical relevance p < 0.001

Journal: Amino Acids

Article Title: Arginine deprivation affects glioblastoma cell adhesion, invasiveness and actin cytoskeleton organization by impairment of β-actin arginylation

doi: 10.1007/s00726-014-1857-1

Figure Lengend Snippet: Arginine deprivation impairs cell motility. a , b Migration tracks of U251 and U87 cells, respectively. Upper panels in a and b tracks of 10 randomly chosen cells; center panels images of migrating cells, and lower panels values of migration rate and mean distance based on tracks shown in upper panels . Values are means ± SD. ***Statistical relevance p < 0.001

Article Snippet: Human glioblastoma U251 MG (U251) and U87 MG (U87) cell lines were purchased from CLS Cell Lines Service (Germany) and monitored for correct genetic profile via microsatellite analyses according to a protocol described earlier (Peickert et al. ).

Techniques: Migration

Arginine deprivation impairs cell migration and invasiveness. Transwell filters not covered ( a ), and covered with Matrigel ( b , c) were used for analyses. Upper and lower panels in a and b images of U251 and U87 stained cells, respectively, taken on the filter trans side. c Images of LN-229 cells, analyzed as in b . Analyses were performed for three independent experiments run in duplicates. d Images of GFP-expressing U251 cells found within the E13 organotypic brain slice. The images represent the confocal 12.3-μm z -section of the planar center of brain slices. Right panel the quantification of GFP-expressing U251 cells within the confocal center of the slice per view area. The quantitative data in a – d are presented as % of control. Values are means ± SD. ***Statistical relevance p < 0.001

Journal: Amino Acids

Article Title: Arginine deprivation affects glioblastoma cell adhesion, invasiveness and actin cytoskeleton organization by impairment of β-actin arginylation

doi: 10.1007/s00726-014-1857-1

Figure Lengend Snippet: Arginine deprivation impairs cell migration and invasiveness. Transwell filters not covered ( a ), and covered with Matrigel ( b , c) were used for analyses. Upper and lower panels in a and b images of U251 and U87 stained cells, respectively, taken on the filter trans side. c Images of LN-229 cells, analyzed as in b . Analyses were performed for three independent experiments run in duplicates. d Images of GFP-expressing U251 cells found within the E13 organotypic brain slice. The images represent the confocal 12.3-μm z -section of the planar center of brain slices. Right panel the quantification of GFP-expressing U251 cells within the confocal center of the slice per view area. The quantitative data in a – d are presented as % of control. Values are means ± SD. ***Statistical relevance p < 0.001

Article Snippet: Human glioblastoma U251 MG (U251) and U87 MG (U87) cell lines were purchased from CLS Cell Lines Service (Germany) and monitored for correct genetic profile via microsatellite analyses according to a protocol described earlier (Peickert et al. ).

Techniques: Migration, Staining, Expressing, Slice Preparation